Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

STATUS

Recruiting
participants needed

45
sponsor

Genzyme, a Sanofi Company

Send

Updated on 19 February 2024

See if I qualify

Summary

Show definitions

Primary Objectives:

To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function
To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome

Secondary Objectives:

To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites
To assess the potential formation of anti-drug antibodies (ADAs) following administration of lademirsen (SAR339375)
To assess the pharmacodynamic effect of lademirsen (SAR339375) on miR-21 and on changes in renal injury and function biomarkers.

Description

The planned length of participation in the study for each subject is up to approximately 110 weeks (from screening through completion of follow-up). This includes:

Screening/baseline period of up to 4 weeks
Double-blind, placebo-controlled treatment period of 48 weeks
Open-label extension treatment period of 48 weeks ( all subject to enter a 48-week open label extension period and receive active treatment with lademirsen (SAR339375))
Post-treatment follow-up period of 10 weeks

Details

Condition	Alport's Syndrome
Age	18year - 55year
Treatment	Placebo, Lademirsen (SAR339375)
Clinical Study Identifier	NCT02855268
Sponsor	Genzyme, a Sanofi Company
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Male or female
	Confirmed diagnosis of Alport syndrome
	Clinical diagnosis (hematuria, family history, hearing loss, ocular change), AND
	Genetic confirmation of Alport Syndrome in the subject or the family member, OR
	Kidney biopsy showing glomerular basement membrane abnormalities (eg, significant thinning, thickening, irregularity or lucencies) consistent with Alport Syndrome
	Age 18-55 years old
	eGFR > 35 ml/min/1.73m^2 and <90 mL/min/1.73m^2 (based on CKD-EPI) at screening
	Renal Function Criteria (patients must meet at least one of the following CRITERIA A, B or C)
	A)Decline in eGFR of ≥4 mL/min/1.73 m^2/year (eGFR slope <= -4) based on a linear regression slope analysis of ≥4 eGFR measurements within 3 years prior to the study and with a minimum of 2-year time span (the last, of the screening measurement, and first eGFR measurements should be separated by at least 2 years). eGFR should be calculated by using either the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation
	B) proteinuria (UPCR) >2000 mg/g (UACR>1000 mg/g)
	C) Age and sex adjusted eGFR (based on CKD-Epi; male 18-23 eGFR<90 mL/min/1.73m^2
	ACE inhibitor and/or ARB, the dosing regimen should be stable for at least 30 days
	prior to screening
	Sexually active female subjects of childbearing potential and sexually mature male subjects must agree to practice true abstinence in line with their preferred and usual lifestyle or to use two acceptable effective methods of contraception for the entire duration of the study and for at least 6 weeks after last dose
	Negative drug screen for opiates, cocaine, heroin, phencyclidine, amphetamines (including ecstasy), barbiturates, benzodiazepines, and cannabinoids. At the Investigator's discretion, subjects prescribed benzodiazepines, cannabinoids, or opiates with positive results on a drug screen may be allowed
	Negative screening results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, and human immunodeficiency virus (HIV) antibody
	Normal biological tests
	Able to understand all study procedures in the informed consent form (ICF) and willing to comply with all aspects of the protocol
Exclusion Criteria
	Causes of chronic kidney disease aside from Alport syndrome (including but not limited to other heritable disorders leading to chronic kidney disease, diabetic nephropathy, hypertensive nephropathy, lupus nephritis, IgA nephropathy)
	ESRD as evidenced by ongoing dialysis therapy or history of renal transplantation
	Any clinically significant illness within 30 days before screening or surgical or medical condition (other than Alport syndrome) that could interfere with the subject's study compliance; confound the study results; impact subject safety; or significantly alter the absorption, distribution, metabolism, or excretion of drugs
	Weight > 110 kg
	Any history of active malignancy within the last 1 year (history of localized basal cell or squamous cell carcinoma and cervical carcinoma in situ that has been excised/appropriately treated or a fully excised malignant lesion with a low probability of recurrence will not be considered exclusionary)
	Prior treatment with Bardoxolone within 90 days prior to screening
	History or presence of alcoholism or drug abuse within 2 years before screening or other concurrent social conditions that would potentially interfere with the subject's study compliance, at the discretion of the Investigator
	Participation in a recent investigational study and receipt of an investigational drug or investigational use of a licensed drug within 30 days or 5 half lives, whichever is longer, prior to screening
	History or presence of hypersensitivity or idiosyncratic, allergic, or other clinically significant reaction to the study drug (including placebo), inactive ingredients, or related compounds (eg, other oligonucleotide products)
	Any other condition or circumstance that, in the opinion of the Investigator, may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety and well-being
	The above information is not intended to contain all considerations relevant to a patient's
	potential participation in a clinical trial

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Sign up as a volunteer to stay informed

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note